Etanercept

Pronunciation: et-a-NER-sept.

Generic name
etanercept
Drug class
Tumour necrosis factor (TNF) inhibitor (biologic, TNF-receptor fusion protein)
Form
Injection (25 mg powder for reconstitution; 25 mg/0.5 mL or 50 mg/mL prefilled syringe or autoinjector pen)
Route
Subcutaneous injection
Legal status
Prescription-only

Availability and supply rules vary by country

Trade names by country: United States · United Kingdom · Canada · Australia · New Zealand

Australia: Enbrel (5) · Full directory

What etanercept is and how it works

Etanercept is a prescription-only injectable biologic medicine that blocks tumour necrosis factor-alpha (TNF-alpha), an inflammation-driving substance in the body. It is used for several long-term inflammatory autoimmune conditions affecting the joints and skin. (1)

Etanercept is usually self-injected under the skin once or twice a week, using a prefilled syringe or autoinjector pen after training from a healthcare professional. Because it affects your immune system, your prescriber will test you for tuberculosis and hepatitis B before you start, and will monitor you throughout treatment for infection and other effects.

Mechanism of action: how etanercept works

Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75-kilodalton (p75) tumour necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1, produced by recombinant DNA technology in a Chinese hamster ovary cell expression system. It binds specifically to TNF and blocks its interaction with cell-surface TNF receptors, rendering TNF biologically inactive. (1)

What etanercept is used for

Rheumatoid arthritis

Used to reduce the signs and symptoms of moderately to severely active rheumatoid arthritis in adults, alone or in combination with methotrexate. (1)

Psoriatic arthritis

Used for active psoriatic arthritis in adults. (1)

Ankylosing spondylitis and non-radiographic axial spondyloarthritis

Used for active ankylosing spondylitis in adults. In the UK, EU, and Australia, etanercept is also approved for non-radiographic axial spondyloarthritis. (1) (2) (5)

Plaque psoriasis

Used for moderate to severe plaque psoriasis in adults, and in children from age 4 (US label) or age 6 (UK/EU label) whose psoriasis has not been controlled well enough with other treatments. (1) (2)

Juvenile idiopathic arthritis

Used for polyarticular juvenile idiopathic arthritis in children from age 2. In the UK, EU, and Australia, this scope is broader and also includes other juvenile idiopathic arthritis subtypes (oligoarthritis, juvenile psoriatic arthritis, and enthesitis-related arthritis). (1) (2) (5)

Before taking etanercept

Do not take / not appropriate for

  • Do not use etanercept if you have sepsis or are at risk of sepsis, or if you have an active, serious infection such as tuberculosis or another opportunistic infection. (all countries) (1) (2) (6)
  • Do not use etanercept together with anakinra -- this combination is an outright contraindication in the New Zealand label (stricter than the US/UK 'not recommended' framing). (New Zealand) (6)
  • Do not use etanercept if you have had an allergic reaction to etanercept or any of its other ingredients. (all countries) (1) (2)

Tell your clinician about

  • Any current infection, or history of recurrent or serious infections, including tuberculosis (or close contact with someone who has had TB).
  • Any history of hepatitis B or hepatitis C infection, since etanercept can cause hepatitis B to reactivate and may worsen hepatitis C.
  • Any history of cancer, heart failure (even mild), or symptoms of nervous system conditions such as multiple sclerosis.
  • Any history of blood disorders (such as low blood cell counts).
  • Any planned vaccinations -- live vaccines should not be given while you are on etanercept.
  • All other medicines you take, especially other biologic medicines for arthritis or psoriasis (such as anakinra or abatacept).
  • Pregnancy, plans for pregnancy, or breastfeeding.
(1) (2) (6)

How to take etanercept

  • Etanercept is usually self-injected under the skin of the thigh, abdomen, or upper arm, once or twice weekly on set days, using a prefilled syringe or autoinjector pen after training from a healthcare professional.
  • Do not change your dose or frequency on your own -- follow your prescriber's plan exactly.
  • Your prescriber will test you for tuberculosis and hepatitis B before your first dose.
  • Rotate injection sites and avoid areas that are tender, bruised, red, or hard.
(1) (2)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6)

Missed dose

If you miss a scheduled injection, contact your prescriber for guidance on when to give the missed dose and how to resume your regular schedule -- do not double up doses on your own.

Overdose

Seek urgent medical attention if too much etanercept may have been given, or if signs of a serious infection or allergic reaction develop after a dose. (1)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Injection-site reactions (redness, itching, swelling, or pain at the injection site) -- very common, usually mild.

What to notice: Injection-site reactions (redness, itching, swelling, or pain at the injection site) -- very common, usually mild.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2)

Upper respiratory tract infections and other mild infections.

What to notice: Upper respiratory tract infections and other mild infections.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Headache.

What to notice: Headache.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2)

Mild allergic reactions such as rash or itching.

What to notice: Mild allergic reactions such as rash or itching.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2)

Serious warnings

Signs of a serious infection, including tuberculosis — boxed_warning

Symptoms: Fever, night sweats, weight loss, persistent cough, feeling very unwell, or a wound or area of skin that will not heal.

Action: Contact your prescriber promptly. You will be screened for TB before starting etanercept and monitored for infection throughout treatment; treatment will be stopped by your prescriber if a serious infection or sepsis develops. (1) (4)

Signs suggestive of lymphoma or other cancer — boxed_warning

Symptoms: Unexplained swollen glands, unusual lumps, unexplained weight loss, or persistent fatigue.

Action: Tell your prescriber promptly -- rare cases of lymphoma and other cancers, some fatal, have occurred with TNF blockers, mostly reported in children, adolescents, and young adults. (1) (6)

Signs of hepatitis B reactivation — high caution

Symptoms: Yellowing of the skin or eyes, dark urine, unusual tiredness, or abdominal pain, especially if you have ever had hepatitis B.

Action: Tell your prescriber immediately -- etanercept can reactivate hepatitis B in carriers; you will be tested before starting and monitored during and after treatment. (1) (2)

Signs of worsening heart failure — high caution

Symptoms: New or worsening shortness of breath, swelling of the ankles or legs, or sudden weight gain.

Action: Contact your prescriber promptly. Use etanercept with caution if you have heart failure -- new or worsening heart failure has been reported. (1) (2) (6)

New or worsening nervous system symptoms — high caution

Symptoms: Numbness, tingling, vision changes, or weakness.

Action: Contact your prescriber -- TNF blockers have rarely been linked to new or worsening central or peripheral nervous system demyelinating conditions (such as multiple sclerosis or Guillain-Barre syndrome). (1) (2) (6)

Signs suggestive of a blood disorder — high caution

Symptoms: Persistent fever, easy bruising or bleeding, or unusual paleness.

Action: Seek prompt medical attention -- rare blood-cell disorders (including pancytopenia and aplastic anaemia, some fatal) have been reported with TNF blockers. (1) (2)

Signs of a serious allergic reaction — emergency

Symptoms: Swelling of the face, lips, tongue, or throat; difficulty breathing; widespread rash or hives.

Action: Seek emergency medical help immediately. (1)

Interactions

  • Combining etanercept with anakinra is not recommended in the US and UK labels because of increased risk of serious infection with no added benefit; the New Zealand label goes further and states this combination is contraindicated. (1) (2) (6)
  • Combining etanercept with abatacept is not recommended -- clinical studies showed increased serious adverse events without added clinical benefit. (1) (2) (6)
  • Live vaccines should not be given while you are being treated with etanercept. (1) (2) (6)
  • Combining etanercept with cyclophosphamide is not recommended, based on data from a Wegener's granulomatosis (GPA) trial. (2)

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

Data are limited. Animal reproduction studies did not show evidence of fetal harm at high maternal exposures, but etanercept crosses the placenta. The UK label advises using adequate contraception during treatment and for three weeks after stopping, and using etanercept in pregnancy only if clearly needed. Discuss the balance of benefits and risks with your prescriber. (1) (2) (3) (4) (5) (6)

Breastfeeding

Etanercept has been detected in human breast milk at low levels but was not detected in a breastfed infant's blood in the source reviewed. Discuss with your prescriber whether breastfeeding is appropriate during your treatment. (1) (2) (3) (4) (5) (6)

Children

Approved for polyarticular juvenile idiopathic arthritis from age 2 and plaque psoriasis from age 4 (US) or age 6 (UK/EU); UK/EU/Australia labels cover additional paediatric JIA subtypes. Always under specialist supervision. Live vaccines should be avoided in infants for 16 weeks after a mother's last dose of etanercept during pregnancy. (1) (2) (3) (4) (5) (6)

Elderly

No specific dose adjustment is described based on age alone, but older adults may be at higher risk of infection generally, so monitoring is important. (1) (2) (3) (4) (5) (6)

Hepatic_impairment

Etanercept has not been specifically studied in significant hepatic impairment in the sources reviewed for this dossier; use with caution if you have hepatitis C, since worsening has been reported. (1) (2) (3) (4) (5) (6)

Renal_impairment

Etanercept has not been specifically studied in significant renal impairment in the sources reviewed for this dossier; discuss with your prescriber if you have kidney disease. (1) (2) (3) (4) (5) (6)

Source_ids

US-DAILYMED-ENBREL-2026,UK-EMC-ENBREL-2026,NZ-MEDSAFE-ENBREL-2026 (1) (2) (3) (4) (5) (6)

Monitoring

Before starting

  • Screening for active and latent tuberculosis (skin test/IGRA and chest X-ray)
  • Hepatitis B testing
  • Assessment for heart failure symptoms
  • Review of vaccination history and any planned live vaccines
  • Baseline blood counts

During treatment

  • Ongoing monitoring for signs and symptoms of infection, including tuberculosis, even if the baseline TB test was negative.
  • Monitoring of hepatitis B carriers during and for several months after treatment.
  • Monitoring for new or worsening heart failure symptoms.
  • Blood counts if any signs suggestive of a blood disorder develop.
  • Ongoing assessment of the benefit of continued treatment against infection and malignancy risk.
(1) (2)

Storage

Store etanercept prefilled syringes/pens or vials in the refrigerator at 2-8°C (36-46°F), in the original carton to protect from light. Do not freeze. Do not shake. A single prefilled syringe or pen may be kept at room temperature for a limited time as directed on the product labelling before use.

Professional information

Clinician-facing context only, sourced from the current US FDA prescribing information and Health Canada product monograph; verify against the current full label in the relevant jurisdiction before prescribing.

United States

Indication: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, juvenile idiopathic arthritis

Dose summary: SC 50 mg once weekly (RA/PsA/AS); plaque psoriasis 50 mg twice weekly for 3 months then 50 mg once weekly; paediatric 0.8 mg/kg once weekly (max 50 mg).

Renal context: Not specifically studied in renal impairment in the source reviewed for this dossier. (1)

Canada

Indication: Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis

Dose summary: 25 mg subcutaneously twice weekly or 50 mg once weekly for adults; weight-based paediatric dosing per indication.

Renal context: Not specifically studied in renal impairment in the source reviewed for this dossier. (4)

Mechanism of action

Hepatic guidance

Not specifically studied in significant hepatic impairment in the sources reviewed; caution advised with hepatitis C given reports of worsening.

Overdose note

Reported overdose experience is limited; manage supportively with monitoring for signs of infection or hypersensitivity. (1)

Frequently asked questions

Is etanercept (Enbrel) available in the US, UK, Europe, Canada, Australia, and New Zealand?

Yes, it is approved and available in all of these regions, as Enbrel, made by Amgen/Immunex in the US and Canada and by Pfizer in the UK, EU, Australia, and New Zealand. (1) (2) (3) (4) (5) (6)

Why do I need to be tested for tuberculosis and hepatitis B before starting etanercept?

Etanercept carries a boxed (highest-level) warning for serious infections, including tuberculosis, because it suppresses part of the immune system. Testing beforehand, and treating any latent TB, reduces the risk of the infection becoming active during treatment. Similarly, etanercept can cause hepatitis B to reactivate in people who carry the virus, so testing and monitoring are required. (1) (4)

Can I take etanercept with anakinra or abatacept?

This is not recommended in the US and UK, because combining these biologic medicines increases the risk of serious infection without added benefit. In New Zealand, combining etanercept with anakinra is an outright contraindication -- your prescriber will not combine these medicines. Always tell your prescriber about all other arthritis or psoriasis medicines you are taking. (1) (2) (6)

What is the mechanism of action of etanercept?

Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75-kilodalton (p75) tumour necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1, produced by recombinant DNA technology in a Chinese hamster ovary cell expression system. It binds specifically to TNF and blocks its interaction with cell-surface TNF receptors, rendering TNF biologically inactive. (1)

What is the generic name of Etanercept?

The generic name is etanercept. (1)

What class of drug is etanercept?

Etanercept is classed as: Tumour necrosis factor (TNF) inhibitor (biologic, TNF-receptor fusion protein). (1)

References

  1. ENBREL (etanercept) injection, for subcutaneous use -- full prescribing informationU.S. Food and Drug Administration / DailyMed (NIH), full prescribing information, Immunex Corporation (Amgen) · United States · accessed 2026-07-30 · source 1
  2. Enbrel 25 mg powder and solvent for solution for injection -- Summary of Product Characteristicselectronic medicines compendium (emc), United Kingdom -- Pfizer Limited · United Kingdom · accessed 2026-07-30 · source 2
  3. Enbrel (etanercept) -- EPAR summary for the publicEuropean Medicines Agency (EMA) · European Union · accessed 2026-07-30 · source 3
  4. ENBREL (etanercept) -- Product MonographHealth Canada product monograph, Amgen Canada Inc. (for Immunex Corporation) · Canada · accessed 2026-07-30 · source 4
  5. ENBREL etanercept (rch) -- ARTG registration and AusPARTherapeutic Goods Administration (TGA), Australia -- ARTG registration, sponsor Pfizer Australia Pty Ltd · Australia · accessed 2026-07-30 · source 5
  6. ENBREL (etanercept) -- New Zealand Data SheetMedsafe (New Zealand regulator), sponsor Pfizer New Zealand Limited · New Zealand · accessed 2026-07-30 · source 6

Brand names by country

Single-ingredient etanercept names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries

United States

  • ENBREL50 mg/mL, 25 mg/.5mL · immunex corporation

United Kingdom

  • Enbrel (2)MHRA licensed emc smpc confirmed · 25 mg powder and solvent for solution for injection, 50 mg prefilled syringe/autoinjector · Pfizer Limited

Canada

  • BRENZYS
  • ENBREL

Australia

  • Enbrel (5)TGA ARTG registered 2003-03-18 confirmed ARTG 90456 PBS listed · 25 mg solution for injection cartridge, 50 mg solution for injection cartridge/auto-injector · Pfizer Australia Pty Ltd

New Zealand

  • Enbrel (6)Medsafe approved confirmed via data sheet · 25 mg powder for injection, 25 mg/0.5 mL and 50 mg/mL prefilled syringe · Pfizer New Zealand Limited
View brands in additional countries.

European Union

Enbrel (3)

This page provides general reference information about etanercept (Enbrel) and is not a substitute for advice from the prescriber managing your treatment. All dosing, screening, and treatment decisions should be made with your prescriber.

Related medicines

Related conditions